CSN Login
Members Online: 11

Phase 1 Clinical trial for a vaccine...

SIROD's picture
SIROD
Posts: 2204
Joined: Jun 2010

CLEVELAND, Ohio -- Susan G. Komen for the Cure is supporting the breast cancer vaccine research of a University Hospitals oncologist with nearly $1 million in grant money.

Dr. Joseph Baar said he hopes to begin enrolling patients in a Phase 1 clinical trial for a vaccine to prevent breast cancer recurrence by early January. The trial, which also will be available at the Cleveland Clinic, is still undergoing the regulatory approval process.

Over the summer, Baar, director of breast cancer research and the Breast Cancer Survivor Program at UH Case Medical Center, received news of the four-year, $996,900 grant to Case Western Reserve University. It is one of 94 grants that the national breast cancer organization awarded for fiscal 2013.

Baar is developing a trial to study the vaccine in women who have had metastatic, or advanced, breast cancer. He is collaborating with immunologist Walter Storkus of the University of Pittsburgh.

The vaccine strengthens the body’s T-cells, killer immune cells instrumental in helping fight off disease. These cells target the environment in which cancer cells thrive, such as blood vessels that help fuel the growth of cancerous tumors. The T-cells cut off the blood supply to those tumors, rather than to the cancer cells themselves.

Storkus identified the proper targets on cancer blood vessels and published the results of studies he conduced in mice.

After hearing Storkus give a talk a few years ago, Baar ask if he could use the science to develop a breast cancer vaccine.

Baar has been studying breast cancer vaccines for years. He is currently analyzing data from a separate study of a vaccine for patients with early-stage triple negative breast cancer.

With this new study, patients will be treated with the chemotherapy gemcitabine before they get the vaccine.

“One of the things we don’t know is when is the best time to administer the vaccine after chemotherapy,” Baar said.

Because of that, the first group of patients in the trial will get the vaccine three days after their chemo has ended. Two subsequent groups will get the vaccine seven and 10 days after chemotherapy.

Everyone will get a second vaccine seven days after the first shot.

reast Cancer Survivor Program at UH Case Medical Center, received news of the four-year, $996,900 grant to Case Western Reserve University. It is one of 94 grants that the national breast cancer organization awarded for fiscal 2013.

Baar is developing a trial to study the vaccine in women who have had metastatic, or advanced, breast cancer. He is collaborating with immunologist Walter Storkus of the University of Pittsburgh.

The vaccine strengthens the body’s T-cells, killer immune cells instrumental in helping fight off disease. These cells target the environment in which cancer cells thrive, such as blood vessels that help fuel the growth of cancerous tumors. The T-cells cut off the blood supply to those tumors, rather than to the cancer cells themselves.

Storkus identified the proper targets on cancer blood vessels and published the results of studies he conduced in mice.

After hearing Storkus give a talk a few years ago, Baar ask if he could use the science to develop a breast cancer vaccine.

Baar has been studying breast cancer vaccines for years. He is currently analyzing data from a separate study of a vaccine for patients with early-stage triple negative breast cancer.

With this new study, patients will be treated with the chemotherapy gemcitabine before they get the vaccine.

“One of the things we don’t know is when is the best time to administer the vaccine after chemotherapy,” Baar said.

Because of that, the first group of patients in the trial will get the vaccine three days after their chemo has ended. Two subsequent groups will get the vaccine seven and 10 days after chemotherapy.

Everyone will get a second vaccine seven days after the first shot.

One of the advantages of the vaccine is that it can be used with all types of metastatic breast cancer because the tumor blood vessel cells are the same. But not all women with breast cancer are good candidates.

A protein called HLA-A2 needs to be present in the breast cancer cells in order for the vaccine to work. About 40 percent of women with metastatic breast cancer have the protein, which is detected by testing the blood, Baar said.

“We’re hoping to enroll 30 patients,” Baar said. “Once we determine [the patients], we’ll collect blood from them. It’s with the cells from their blood that we would make the vaccine.”

The vaccine will be made at a specialized lab in Pittsburgh, then sent back to Cleveland where it will be administered.

http://www.cleveland.com/healthfit/index.ssf/2013/10/komen_gives_nearly_1_million_f.html

VickiSam's picture
VickiSam
Posts: 8499
Joined: Aug 2009

Thank you ..  Doris for bringing this forward ..

 

Vicki Sam

camul's picture
camul
Posts: 2135
Joined: Dec 2010

The most they can say is no!! nfortunately, some of the trials (per onco) are on hold if theynuage govt. funding.
hanks Doris. These are tye immune gaccines they uave been working on for year
Hugs,
Carol

SIROD's picture
SIROD
Posts: 2204
Joined: Jun 2010

I hope one day, one of them will work.

Hugs to you too,

Doris

SIROD's picture
SIROD
Posts: 2204
Joined: Jun 2010

I've complained so often about Komen's money in the past.  I am glad to see that it is being used.

Maybe the new CEO is making a difference.

Doris

SIROD's picture
SIROD
Posts: 2204
Joined: Jun 2010

I've complained so often about Komen's money in the past.  I am glad to see that it is being used.

Maybe the new CEO is making a difference.

Doris

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network